Meta-analyses of four eosinophil related gene variants in coronary heart disease

Jiangfang Lian1, Yi Huang, R Stephanie Huang

  • 1Ningbo Medical Center, Lihuili Hospital, Ningbo University, Ningbo, 315041, Zhejiang, China.

Insights

Genetic variants in eosinophil-related genes were studied for their link to coronary heart disease (CHD). The SH2B3 gene variant rs3184504 showed a significant association with CHD risk in European and South Asian populations.

Area of Science:

  • Genetics
  • Cardiovascular Disease Epidemiology
  • Immunology

Background:

  • Eosinophils play a role in inflammation and immune responses.
  • Genetic variations can influence susceptibility to complex diseases like coronary heart disease (CHD).
  • Previous research suggests potential links between eosinophil-related genes and cardiovascular health.

Purpose of the Study:

  • To investigate the association between four specific eosinophil-related gene variants (rs12619285, rs1420101, rs3184504, and rs4143832) and the risk of developing coronary heart disease (CHD).
  • To evaluate the contribution of these genetic variants to CHD risk across different ethnic populations.

Main Methods:

  • Conducted systematic literature searches across multiple databases (MEDLINE, EMBASE, Web of Science, CNKI, Wanfang).
  • Performed meta-analyses of existing studies and a new case-control study (162 CHD cases, 119 controls).
  • Focused meta-analysis on rs3184504 in the SH2B3 gene using 19 study stages and 94,555 participants.

Main Results:

  • A significant association was found between the rs3184504 variant in the SH2B3 gene and increased CHD risk in European and South Asian populations (OR = 1.13, 95% CI = 1.10-1.16, p < 0.0001).
  • No significant association was observed for rs12619285, rs1420101, and rs4143832 with CHD risk when combining case-control data with previous studies.
  • The four genetic variants did not show a significant contribution to CHD risk in the Han Chinese population.

Conclusions:

  • The rs3184504 variant of the SH2B3 gene is significantly associated with coronary heart disease risk in European and South Asian populations.
  • No significant association was found for the studied eosinophil-related gene variants with CHD risk in the Han Chinese population.
  • These findings highlight population-specific genetic influences on coronary heart disease susceptibility.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...